Wells Fargo downgraded Zymeworks (ZYME) to Equal Weight from Overweight with an unchanged price target of $12. The firm believes the shares are “fully valued” following the company’s Q3 report. Wells cites valuation for the downgrade.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.